RGEN
REPLIGEN CORP
Biological Products, (No Diagnostic Substances)- 売上
- $738m
- 時価総額
- $8.1bn
株価 $143.60 · 100株 1万円
| 期 | 23/12 | 24/12 | 25/12 |
|---|---|---|---|
| 売上 | $632m | $634m | $738m |
| 成長率 | — | 0.3% | 16.4% |
| 総利益 | $278m | $275m | $386m |
| 総利益率 | 44.0% | 43.3% | 52.3% |
| 販管費 | $219m | $263m | $291m |
| 販管費率 | 34.6% | 41.5% | 39.4% |
| 営利 | $48m | ▲$35m | $55m |
| 営利率 | 7.5% | ▲5.5% | 7.5% |
| 純利益 | $36m | ▲$26m | $49m |
| PBR | 4.1 | 4.1 | 3.8 |
| PSR | 12.8 | 12.7 | 10.9 |
| PGPR | 29.0 | 29.4 | 20.9 |
| PER | 227 | — | 165 |
| ﾈｯﾄｷｬｯｼｭ | $751m | $232m | $24m |
| EV/EBITDA | 62.9 | 226.6 | 60.0 |
| Rule of 40 | — | ▲5% | 24% |
| セールス効率 | — | ▲9% | 411% |
※Rule of 40は売上成長率＋営業利益率、セールス効率は売上総利益増加÷販管費増加（販管費増のときのみ）